What's Happening?
Reps. Greg Steube, R-Fla., and Dina Titus, D-Nev., have introduced the Preventing Risky Importation of Monkeys to Avoid Toxic Exposures (PRIMATE) Act. This legislation aims to prohibit the importation of nonhuman primates into the United States, with
limited exceptions. The move is part of a broader federal shift towards reducing reliance on animal testing in biomedical research. The Oregon National Primate Research Center (ONPRC) is also transitioning to focus on alternatives to animal testing, following a strategic framework approved by its board. This development is part of a larger trend, with the U.S. Food and Drug Administration and the National Institutes of Health investing in human-based research and New Approach Methodologies (NAMs).
Why It's Important?
The introduction of the PRIMATE Act and the shift at ONPRC represent significant changes in the landscape of biomedical research in the U.S. By reducing the importation and use of primates in research, these actions could lead to more ethical research practices and potentially more accurate human-relevant scientific outcomes. This shift could impact various stakeholders, including research institutions, pharmaceutical companies, and animal rights organizations. The legislation and institutional changes reflect growing public and governmental support for reducing animal testing, which could lead to increased funding and development of alternative research methods.
What's Next?
As the PRIMATE Act progresses through Congress, it will likely face scrutiny and debate from various stakeholders, including research institutions and animal rights groups. The transition at ONPRC will involve moving some primates to other institutions and exploring opportunities to transfer animals to sanctuaries. The broader federal shift towards NAMs will continue, with ongoing investments in human-based research methods. These developments may prompt other research centers to reevaluate their use of animal testing and consider similar transitions.
